BiotechTube
MicroQuin

MicroQuin

Seattle, United States· Est.
microquin.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

MicroQuin is a private, preclinical-stage biotech developing first-in-class therapeutics that target the IntraCellular Environment (ICE) to treat cancer, viral infections, and neurodegeneration. Its core hypothesis is that disease progression is driven by destabilization of the cellular interior, and its drugs aim to restore balance by modulating specific ICE regulators. The company has garnered non-dilutive funding from government grants and established a key collaboration with Eli Lilly's TuneLab, positioning its lead oncology program for potential IND-enabling studies. MicroQuin represents a high-risk, high-reward venture targeting fundamental biological mechanisms across multiple major therapeutic areas.

OncologyInfectious DiseaseNeurology

Technology Platform

ICE (IntraCellular Environment) Regulation Platform: A therapeutic approach targeting proteins that regulate the internal environment of the cell. The platform develops small molecules that either inhibit or activate these ICE regulators to rebalance cellular conditions destabilized by disease, with applications in oncology, virology, and neurodegeneration.

Funding History

2
Total raised:$3M
Grant$500K
Seed$2.5M

Opportunities

If successful, MicroQuin's ICE platform could yield first-in-class, broad-spectrum therapeutics for massive markets like oncology and virology with potentially superior safety profiles.
The collaboration with Eli Lilly provides significant validation and resources to accelerate development.
Non-dilutive grant funding from entities like the CDMRP extends the company's runway and de-risks early research.

Risk Factors

The core scientific risk is high, as the ICE hypothesis is novel and unproven in humans, with a significant chance of clinical failure.
The ambitious claim of targeting 'all cancers' with one mechanism faces immense biological and clinical hurdles.
As a preclinical, pre-revenue company, it is dependent on future fundraising, which may be challenging if milestones are not met.

Competitive Landscape

MicroQuin's approach is highly differentiated, with few, if any, direct competitors targeting intracellular environmental regulation as a primary therapeutic mechanism. However, it competes indirectly with all developers of targeted cancer therapies, antivirals, and neuroprotective drugs. Its success depends on demonstrating superior efficacy or safety compared to established and emerging modalities in each crowded field.

More companies in United States →